This report describes the reach and scope of Medicare's Part D Senior Savings model, which has lower, fixed cost sharing for a specified set of model drugs.
Government negotiation of Medicare drug prices—even for a small set of older, single-source drugs—is a remarkable policy development. But how exactly will the government do it?
Increases in vertical integration were not associated with changes in medication adherence rates. However, adherence rates after vertical integration declined for non-Whites, patients over 80 years old, and patients with greater comorbidities.
On February 7, 2022, the RAND Corporation convened a Technical Expert Panel web meeting to gather input about the potential development of a measure to capture value-based care arrangements Medicare Advantage organizations have with their contracted providers.
This cross-sectional study evaluates the association of a cap on monthly out-of-pocket spending on high-cost drugs with use of these drugs and out-of-pocket spending in California in 2015 and 2016.
The RAND team gathered input from experts about stratified reporting by Part D low-income subsidy (LIS) and dual eligibility (DE), and disability and assessing social risk factors of Medicare Advantage (MA) and Part D contract beneficiaries.
Although generic use has increased markedly over time in Part D, substantial variation across plans persists in a number of common therapeutic classes.
President Joe Biden addressed a joint session of Congress, summarizing his administration's early COVID-19 response and outlining plans that aim to loosen the pandemic's year-long grip on a weary nation. The speech reflected the fact that the United States faces policy challenges across a wide range of domains.
To develop and assess the reliability and validity of composite measures of reasons for disenrollment from Medicare Advantage and prescription drug plans.
On November 12, 2020, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input about social risk factors and approaches for ensuring accurate performance measurement.
On November 19, 2020, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input about stratified reporting of performance and approaches to reduce disparities in Medicare Advantage (MA) and Part D Contracts.
The Military Health System provides health and drug coverage to beneficiaries through TRICARE. This report describes the TRICARE pharmacy benefit and the trade-offs in TRICARE pharmacy policies between increasing access and controlling costs.
On July 22, 2020, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input on analyses that could be conducted to further enhance the Medicare Advantage (MA) and Part D Contract Star Ratings program.
The national growth in opioid supply explains 75% of the national rise in opioid treatment admissions and the diversion component is a critical driver of the opioid epidemic.
The authors argue that, conceptually, the main advantage of subscription models over traditional prescription drug payment arrangements is that they could reduce some sources of uncertainty in spending for payers and in revenue for manufacturers.
This study found an increase in the rate of overdose after Medicare Part D coverage began to include benzodiazepines among adults aged 65 to 69 years and 80 years or older and an increase in the rate of fall-related injury in adults 80 years or older.
On November 7, 2019, the RAND Corporation convened a Technical Expert Panel (TEP) web meeting to gather input on analyses that could be conducted to further enhance the Medicare Advantage (MA) and Part D Contract Star Ratings program.
Most Americans, including Congress and the president, agree that prescription drug prices are too high. Policy proposals from both major parties could promise some relief. Several of them look to drug prices in other countries to help set prices in the United States.
